247 related articles for article (PubMed ID: 22313962)
1. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis.
Sacre K; Hunt PW; Hsue PY; Maidji E; Martin JN; Deeks SG; Autran B; McCune JM
AIDS; 2012 Apr; 26(7):805-14. PubMed ID: 22313962
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Coinfection Is Associated with Increased Vascular-Homing CD57
Chen B; Morris SR; Panigrahi S; Michaelson GM; Wyrick JM; Komissarov AA; Potashnikova D; Lebedeva A; Younes SA; Harth K; Kashyap VS; Vasilieva E; Margolis L; Zidar DA; Sieg SF; Shive CL; Funderburg NT; Gianella S; Lederman MM; Freeman ML
J Immunol; 2020 May; 204(10):2722-2733. PubMed ID: 32229536
[TBL] [Abstract][Full Text] [Related]
3. Association of circulating fractalkine (CX3CL1) and CX3CR1(+)CD4(+) T cells with common carotid artery intima-media thickness in patients with chronic kidney disease.
Yadav AK; Lal A; Jha V
J Atheroscler Thromb; 2011; 18(11):958-65. PubMed ID: 21873805
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus-induced effector T cells cause endothelial cell damage.
van de Berg PJ; Yong SL; Remmerswaal EB; van Lier RA; ten Berge IJ
Clin Vaccine Immunol; 2012 May; 19(5):772-9. PubMed ID: 22398244
[TBL] [Abstract][Full Text] [Related]
5. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses.
Hsue PY; Hunt PW; Sinclair E; Bredt B; Franklin A; Killian M; Hoh R; Martin JN; McCune JM; Waters DD; Deeks SG
AIDS; 2006 Nov; 20(18):2275-83. PubMed ID: 17117013
[TBL] [Abstract][Full Text] [Related]
6. Human cytomegalovirus chemokine receptor US28 induces migration of cells on a CX3CL1-presenting surface.
Hjortø GM; Kiilerich-Pedersen K; Selmeczi D; Kledal TN; Larsen NB
J Gen Virol; 2013 May; 94(Pt 5):1111-1120. PubMed ID: 23303826
[TBL] [Abstract][Full Text] [Related]
7. The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients.
Combadière B; Faure S; Autran B; Debré P; Combadière C
AIDS; 2003 Jun; 17(9):1279-90. PubMed ID: 12799549
[TBL] [Abstract][Full Text] [Related]
8. CD4
Slot MC; Kroon AA; Damoiseaux JGMC; Theunissen R; Houben AJHM; de Leeuw PW; Tervaert JWC
Rheumatol Int; 2017 May; 37(5):791-798. PubMed ID: 28084533
[TBL] [Abstract][Full Text] [Related]
9. Progression to CMV end-organ disease in HIV-1-infected individuals despite abundance of highly differentiated CMV-specific CD8+ T-cells.
Bronke C; Westerlaken GH; Miedema F; Tesselaar K; van Baarle D
Immunol Lett; 2005 Mar; 97(2):215-24. PubMed ID: 15752561
[TBL] [Abstract][Full Text] [Related]
10. Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4.
Garg A; Trout R; Spector SA
Sci Rep; 2017 Mar; 7():44485. PubMed ID: 28338007
[TBL] [Abstract][Full Text] [Related]
11. Chemokine CX3CL1 and its receptor CX3CR1 are associated with human atherosclerotic lesion volnerability.
Zhang X; Feng X; Cai W; Liu T; Liang Z; Sun Y; Yan C; Han Y
Thromb Res; 2015 Jun; 135(6):1147-53. PubMed ID: 25845619
[TBL] [Abstract][Full Text] [Related]
12. CX3CL1 and IL-15 Promote CD8 T cell chemoattraction in HIV and in atherosclerosis.
Panigrahi S; Chen B; Fang M; Potashnikova D; Komissarov AA; Lebedeva A; Michaelson GM; Wyrick JM; Morris SR; Sieg SF; Paiardini M; Villinger FJ; Harth K; Kashyap VS; Cameron MJ; Cameron CM; Vasilieva E; Margolis L; Younes SA; Funderburg NT; Zidar DA; Lederman MM; Freeman ML
PLoS Pathog; 2020 Sep; 16(9):e1008885. PubMed ID: 32976527
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.
Bronke C; Palmer NM; Jansen CA; Westerlaken GH; Polstra AM; Reiss P; Bakker M; Miedema F; Tesselaar K; van Baarle D
J Infect Dis; 2005 Mar; 191(6):873-80. PubMed ID: 15717261
[TBL] [Abstract][Full Text] [Related]
14. Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery.
Gómez-Mora E; Massanella M; García E; Giles D; Bernadó M; Urrea V; Carrillo J; Ouchi D; Puig J; Negredo E; Clotet B; Blanco J; Cabrera C
PLoS One; 2017; 12(9):e0184433. PubMed ID: 28934217
[TBL] [Abstract][Full Text] [Related]
15. Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28 T cells in RA patients and correlation with atherosclerotic damage.
Pingiotti E; Cipriani P; Marrelli A; Liakouli V; Fratini S; Penco M; Giacomelli R
Ann N Y Acad Sci; 2007 Jun; 1107():32-41. PubMed ID: 17804530
[TBL] [Abstract][Full Text] [Related]
16. Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction.
Bolovan-Fritts CA; Spector SA
Blood; 2008 Jan; 111(1):175-82. PubMed ID: 17895402
[TBL] [Abstract][Full Text] [Related]
17. Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery.
Singh KP; Howard JL; Wild SP; Jones SL; Hoy J; Lewin SR
Clin Immunol; 2007 Aug; 124(2):200-6. PubMed ID: 17574925
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease.
Patel A; Jagadesham VP; Porter KE; Scott DJ; Carding SR
Eur J Vasc Endovasc Surg; 2008 Jul; 36(1):20-7. PubMed ID: 18296082
[TBL] [Abstract][Full Text] [Related]
19. Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes.
Kobayashi T; Okamoto S; Iwakami Y; Nakazawa A; Hisamatsu T; Chinen H; Kamada N; Imai T; Goto H; Hibi T
Inflamm Bowel Dis; 2007 Jul; 13(7):837-46. PubMed ID: 17285595
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus (CMV) Epitope-Specific CD4
Abana CO; Pilkinton MA; Gaudieri S; Chopra A; McDonnell WJ; Wanjalla C; Barnett L; Gangula R; Hager C; Jung DK; Engelhardt BG; Jagasia MH; Klenerman P; Phillips EJ; Koelle DM; Kalams SA; Mallal SA
J Immunol; 2017 Nov; 199(9):3187-3201. PubMed ID: 28972094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
